Eine Studie zum Testen der Zugabe des Medikaments Cabozantinib zur Chemotherapie bei Patienten mit neu diagnostiziertem Osteosarkom
Eine Durchführbarkeits- und randomisierte Phase-2/3-Studie des VEFGR2/MET-Inhibitors Cabozantinib in Kombination mit einer zytotoxischen Chemotherapie bei neu diagnostiziertem Osteosarkom
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients with newly diagnosed osteosarcoma. Cabozantinib is in a class of medications called kinase inhibitors which block protein signals affecting new blood vessel formation and the ability to activate growth signaling pathways. This may help slow the growth of tumor cells. The drugs used in standard chemotherapy for this trial are methotrexate, doxorubicin, and cisplatin (MAP). Methotrexate stops cells from making DNA and may kill tumor cells. It is a type of antimetabolite. Doxorubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of tumor cells in the body. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Adding cabozantinib to standard chemotherapy may work better in treating newly diagnosed osteosarcoma.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine the feasibility of adding cabozantinib S-malate (cabozantinib) to standard MAP (high dose methotrexate, doxorubicin hydrochloride [doxorubicin], and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor.
II. To determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival (EFS) than MAP chemotherapy alone in patients with localized, resectable osteosarcoma.
III. To determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival (EFS) than MAP chemotherapy alone in patients with metastatic, pelvic and unresectable osteosarcoma.
SECONDARY OBJECTIVES:
I. To determine whether MAP chemotherapy plus cabozantinib results in more favorable overall survival (OS) than MAP chemotherapy alone in patients with localized, resectable osteosarcoma.
II. To determine whether MAP chemotherapy plus cabozantinib results in more favorable overall survival (OS) than MAP chemotherapy alone in patients with metastatic, pelvic and unresectable osteosarcoma.
III. To prospectively validate that elevated circulating tumor DNA (ctDNA) levels greater than or equal to 5% at the time of diagnosis are associated with increased risk of EFS-event in patients with localized, resectable osteosarcoma.
IV. To prospectively validate that elevated ctDNA levels greater than or equal to 5% at the time of diagnosis are associated with increased risk of EFS-event in patients with metastatic, pelvic and unresectable osteosarcoma.
V. To prospectively validate that elevated ctDNA levels greater than or equal to 3% after initiation of therapy and prior to definitive surgery are associated with increased risk of EFS-event in patients with localized, resectable osteosarcoma.
VI. To prospectively validate that elevated ctDNA levels greater than or equal to 3% after initiation of therapy and prior to definitive surgery are associated with increased risk of EFS-event in patients with metastatic, pelvic and unresectable osteosarcoma.
VII. To determine whether MAP chemotherapy plus cabozantinib results in increased symptom burden and decreased tolerability to patients as measured by patient reported therapy-specific acute toxicities (Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events [PRO-CTCAE]).
EXPLORATORY OBJECTIVES:
I. To determine the rate of good histologic response (> 90%) of resected primary tumor specimens following neoadjuvant chemotherapy with MAP plus cabozantinib and compare with response rates for MAP chemotherapy alone.
II. To describe the toxicities of the addition of cabozantinib to MAP chemotherapy in patients with newly diagnosed osteosarcoma.
III. To compare the probability of Grade 3 or higher port site wound complications on the MAP plus cabozantinib regimen to that of MAP chemotherapy alone in patients with newly diagnosed osteosarcoma who received a port for the administration of chemotherapy.
IV. To describe frequency of application of local control methods (surgery, hypofractionated stereotactic body radiotherapy, or radiofrequency ablation) for extrapulmonary metastatic osteosarcoma.
V. To compare total cumulative delivered doses of MAP chemotherapy agents between standard and experimental arms across multiple phases of therapy.
VI. To assess the pharmacokinetics of cabozantinib when administered concomitantly with standard chemotherapy agents during feasibility.
VII. To collect pulmonary metastatic lesions, paired primary tumor tissue, and serial blood samples for tumor profiling, liquid biopsies, and future testing of correlative biology studies.
VIII. To determine whether ctDNA at diagnosis and early on-treatment, as a continuous measurement of ctDNA burden, is associated with an increased risk of EFS-event in patients with newly diagnosed osteosarcoma.
IX. To evaluate whether the magnitude of change in ctDNA levels from diagnosis to planned surgical procedure is associated with risk of EFS-event in patients with newly diagnosed osteosarcoma.
X. To determine whether ctDNA levels greater than or equal to 3% after planned surgical procedures are associated with increased risk of EFS-event.
XI. To describe the presence of specific copy-number alterations, including MYC amplifications, detected in ctDNA and matched diagnostic tumor samples in patients with newly diagnosed osteosarcoma and determine whether frequently occurring copy-number alterations are associated with increased risk of EFS-event.
XII. To determine whether ctDNA burden is predictive of response to the experimental therapy in patients with newly diagnosed osteosarcoma.
XIII. To prospectively compare the impact of combination therapy on symptom bother as measured by the Functional Assessment of Cancer Therapy-General Questionnaire (FACT-G) item GP5 in patients with osteosarcoma receiving MAP chemotherapy with or without cabozantinib, and to assess the relationship between symptom bother and number of patient-reported acute toxicities (as measured by the PRO-CTCAE).
OUTLINE: This is a dose-escalation study of cabozantinib (Feasibility Phase) followed by a randomized phase II/III study (Efficacy Phase).
FEASIBILITY PHASE (CLOSED TO ACCRUAL 05/09/2025): Patients receive cabozantinib orally (PO), methotrexate intravenously (IV), doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles. Patients are then considered for appropriate local control. Then they receive "consolidation" with methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, followed by cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, and cabozantinib PO, methotrexate IV, and doxorubicin IV for two 35-day cycles. Patients then receive cabozantinib PO for six 28-day "maintenance" cycles.
EFFICACY PHASE: Patients with standard risk osteosarcoma are randomized to Arm A or Arm B. Patients with high risk osteosarcoma are randomized to Arm C or Arm D.
ARM A: Standard risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive "consolidation" with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles.
ARM B: Standard risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive one 35-day "consolidation" cycle with methotrexate IV, doxorubicin IV, and cisplatin IV, then a second 35-day "consolidation" cycle with cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV, followed by two additional 35-day "consolidation" cycles with cabozantinib PO, methotrexate IV, and doxorubicin IV. Patients then receive cabozantinib PO for six 28-day "maintenance" cycles.
ARM C: High risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive "consolidation" with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles.
ARM D: High risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive one 35-day "consolidation" cycle with methotrexate IV, doxorubicin IV, and cisplatin IV, then a second 35-day "consolidation" cycle with cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV, followed by two additional 35-day "consolidation" cycles with cabozantinib PO, methotrexate IV, and doxorubicin IV. Patients then receive cabozantinib PO for six 28-day "maintenance" cycles.
All patients also undergo X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) or bone scintigraphy at diagnosis and additional time points throughout the trial. All patients also undergo collection of blood samples during screening and on study.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australien, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Queensland Children's Hospital
-
-
South Australia
-
North Adelaide, South Australia, Australien, 5006
- Women's and Children's Hospital-Adelaide
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Monash Medical Center-Clayton Campus
-
Parkville, Victoria, Australien, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Perth Children's Hospital
-
-
-
-
-
Québec, Kanada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Kanada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Kanada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Christchurch, Neuseeland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Neuseeland, 1145
- Starship Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Children's Hospital of Alabama
-
-
Arizona
-
Mesa, Arizona, Vereinigte Staaten, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Mayo Clinic Hospital in Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Vereinigte Staaten, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Vereinigte Staaten, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, Vereinigte Staaten, 90095
- Mattel Children's Hospital UCLA
-
Madera, California, Vereinigte Staaten, 93636
- Valley Children's Hospital
-
Oakland, California, Vereinigte Staaten, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Vereinigte Staaten, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Vereinigte Staaten, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Vereinigte Staaten, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Vereinigte Staaten, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Vereinigte Staaten, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Myers, Florida, Vereinigte Staaten, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Vereinigte Staaten, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Vereinigte Staaten, 33176
- Miami Cancer Institute
-
Orlando, Florida, Vereinigte Staaten, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Vereinigte Staaten, 32803
- AdventHealth Orlando
-
Orlando, Florida, Vereinigte Staaten, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Vereinigte Staaten, 32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Vereinigte Staaten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Lurie Children's Hospital-Chicago
-
Peoria, Illinois, Vereinigte Staaten, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Riley Hospital for Children
-
-
Iowa
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Vereinigte Staaten, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Vereinigte Staaten, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Vereinigte Staaten, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital Cancer Center
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- C S Mott Children's Hospital
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Rogel Cancer Center
-
Brownstown, Michigan, Vereinigte Staaten, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Vereinigte Staaten, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Vereinigte Staaten, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Jackson, Michigan, Vereinigte Staaten, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Bronson Methodist Hospital
-
Novi, Michigan, Vereinigte Staaten, 48377
- Henry Ford Medical Center-Columbus
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Corewell Health Children's
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Henry Ford West Bloomfield Hospital
-
Wyandotte, Michigan, Vereinigte Staaten, 48192
- Henry Ford Wyandotte Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Vereinigte Staaten, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Vereinigte Staaten, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Vereinigte Staaten, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Vereinigte Staaten, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Albany Medical Center
-
Buffalo, New York, Vereinigte Staaten, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Vereinigte Staaten, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Vereinigte Staaten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Vereinigte Staaten, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Vereinigte Staaten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Vereinigte Staaten, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Vereinigte Staaten, 10595
- New York Medical College
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Novant Health Presbyterian Medical Center
-
Charlotte, North Carolina, Vereinigte Staaten, 28210
- Atrium Health Pineville/LCI-Pineville
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43205
- Nationwide Children's Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
Dayton, Ohio, Vereinigte Staaten, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Vereinigte Staaten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Vereinigte Staaten, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Prisma Health Richland Hospital
-
Gaffney, South Carolina, Vereinigte Staaten, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- BI-LO Charities Children's Cancer Center
-
Greer, South Carolina, Vereinigte Staaten, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Vereinigte Staaten, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Vereinigte Staaten, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Vereinigte Staaten, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Cook Children's Medical Center
-
Houston, Texas, Vereinigte Staaten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Vereinigte Staaten, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Vereinigte Staaten, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Vereinigte Staaten, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Vereinigte Staaten, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
Norfolk, Virginia, Vereinigte Staaten, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, Vereinigte Staaten, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Vereinigte Staaten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Vereinigte Staaten, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Vereinigte Staaten, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Children's Hospital of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients must be < 40 years of age at the time of enrollment.
- Patients must have a body surface area of >= 0.8 m^2 at the time of enrollment.
- Patients must have histologic diagnosis (by institutional pathologist) of newly diagnosed high grade osteosarcoma. Primary tumors of all extremity and axial sites are eligible as long as diagnosis of high-grade osteosarcoma is established. Osteosarcoma as a second malignancy is eligible if no prior exposure to systemic chemotherapies.
- Feasibility Phase (NOTE: as of Amendment #2B, the feasibility phase has been completed) Patients must have metastatic disease and a resectable primary tumor. Designation of a primary tumor as resectable will be determined at the time of diagnosis by the institutional multidisciplinary team.
For this study, metastatic disease is defined as one or more of the following:
-
Lesions which are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a bone or body cavity with the primary tumor. Skip lesions in the same bone as the primary tumor do not constitute metastatic disease. Skip lesions in an adjacent bone are considered bone metastases.
-
Lung metastases: defined as biopsy-proven metastasis or the presence of one or more pulmonary lesions >= 5 mm, OR multiple pulmonary lesions >= 3 mm or greater in size.
-
Bone metastases: Areas suspicious for bone metastasis based on fludeoxyglucose F-18 (18F-FDG)-positron emission tomography (PET) scan (or whole body technetium-99 bone scan if 18F-FDG-PET is unavailable at the treating institution) require confirmatory biopsy or supportive anatomic imaging of at least one suspicious site with either magnetic resonance imaging (MRI) or computed tomography (CT) (whole body 18F-FDG-PET/CT or 18F-FDG-PET/MR scans are acceptable).
- Efficacy Phases (Phase 2/3) NOTE: as of Amendment #2B, the efficacy phase is open for enrollment.
Patients with both localized and metastatic disease are eligible for the efficacy phase, regardless of resectability. Patients will be enrolled to two separate cohorts:
-
Cohort 1 (Standard Risk): Patients with non-pelvic primary osteosarcoma deemed to be resectable at the time of diagnosis by the institutional multidisciplinary team, without evidence of metastatic lesions.
-
Cohort 2 (High-Risk): Patients with a primary pelvic tumor, a primary tumor designated as unresectable by the institutional multidisciplinary team, AND/OR radiographic evidence of metastatic lesions.
- A serum creatinine based on age/sex as follows (within 7 days prior to enrollment unless otherwise indicated):
-
(Age: Maximum Serum Creatinine [mg/dL]; Sex)
- 1 month to < 6 months: 0.4 (male); 0.4 (female)
- 6 months to < 1 year: 0.5 (male); 0.5 (female)
- 1 to < 2 years: 0.6 (male); 0.6 (female)
- 2 to < 6 years: 0.8 (male); 0.8 (female)
- 6 to < 10 years: 1 (male); 1 (female)
- 10 to < 13 years: 1.2 (male); 1.2 (female)
- 13 to < 16 years: 1.5 (male); 1.4 (female)
- >= 16 years: 1.7 (male); 1.4 (female)
-
OR - a 24 hour urine creatinine clearance >= 70 mL/min/1.73 m^2
-
OR - a glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard).
-
Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility.
- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment unless otherwise indicated)
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment unless otherwise indicated)
-
-
Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
- No history of congenital prolonged corrected QT (QTc) syndrome, New York Heart Association (NYHA) Class III or IV congestive heart failure, unstable angina pectoris, serious cardiac arrhythmias
-
Shortening fraction of >= 27%, or
-
Ejection fraction of >= 50%
-
Corrected QT interval by Fridericia (QTcF) < 480 msec on electrocardiogram. Patients with Grade 1 prolonged QTc (450-480 msec) at time of study enrollment should have correctable causes of prolonged QTc addressed if possible (i.e., electrolytes, medications).
- Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to enrollment unless otherwise indicated)
- Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment) (within 7 days prior to enrollment unless otherwise indicated)
- Hemoglobin >= 8.0 g/dL (within 7 days prior to enrollment unless otherwise indicated)
- International normalized ratio (INR) =< 1.5 (within 7 days prior to enrollment unless otherwise indicated)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible as long as they are NOT receiving anti-retroviral agents that are strong inhibitors or inducers of CYP3A4, CYP2D6, and/or MRP2 transporter protein.
- All patients and/or their parents or legal guardians must sign a written informed consent.
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.
Exclusion Criteria:
- Patients who have received previous systemic therapy for osteosarcoma or a prior oncologic diagnosis.
- Patients who have central nervous system metastases.
- Patients with central cavitating pulmonary lesions invading or encasing any major blood vessels in the lung.
- Patients who are unable to swallow tablets. Tablets cannot be crushed or chewed.
- Patients with gastrointestinal disorders including active disorders associated with a high risk of perforation or fistula formation. Specifically, no clinically significant gastrointestinal (GI) bleeding, GI perforation, bowel obstruction, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment.
- Patients with active bleeding or bleeding diathesis. No clinically significant hematuria, hematemesis, or hemoptysis or other history of significant bleeding within 3 months prior to enrollment.
- Patients with uncompensated or symptomatic hypothyroidism. Patients who have hypothyroidism controlled with thyroid replacement hormone are eligible.
- Patients with moderate to severe hepatic impairment (Child-Pugh B or C).
- Patients who have had primary tumor resection or attempted curative resection of metastases prior to enrollment.
- Patients who have undergone other major surgical procedure (eg, laparotomy) within 14 days prior to enrollment. Thoracoscopic procedures for diagnostic purposes (biopsy of lung nodule) and central access such as port-a-cath placement are allowed.
- Patients with a history of serious or non-healing wound or bone fracture (pathologic fracture of primary tumor is not considered exclusion).
- Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of cabozantinib.
- Patients with previously identify allergy or hypersensitivity to components of the study treatment formulations.
- Patients who are receiving any other investigational agent not defined within this protocol are not eligible.
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
- Patients who received enzyme-inducing anticonvulsants within 14 days prior to enrollment.
- Patients with a prior history of hypertension (> 95th percentile for age, height, and sex for patients < 18 years and > 140/90 mmHg for patients >= 18 years requiring medication for blood pressure control.
- Patients who are receiving drugs that prolong QTc.
- Patients receiving anticoagulation with oral coumarin agents (eg warfarin), direct thrombin inhibitors (eg dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (eg, clopidogrel). Low dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH and direct factor Xa inhibitors rivaroxaban or apixaban are allowed in subjects who are on a stable dose for at least 6 weeks before the first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimen.
- Patients receiving strong CYP3A4 inducers or strong CYP3A4 inhibitors.
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.
- Lactating females who plan to breastfeed their infants.
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of protocol therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Efficacy Phase Arm A (MAP)
Standard risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive "consolidation" with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additional time points throughout the trial. All patients also undergo collection of blood samples during screening and on study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo surgery
Andere Namen:
Undergo bone scintography
Andere Namen:
Undergo X-ray
Andere Namen:
|
|
Experimental: Efficacy Phase Arm B (cabozantinib, MAP)
Standard risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive one 35-day "consolidation" cycle with methotrexate IV, doxorubicin IV, and cisplatin IV, then a second 35-day "consolidation" cycle with cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV, followed by two additional 35-day "consolidation" cycles with cabozantinib PO, methotrexate IV, and doxorubicin IV. Patients then receive cabozantinib PO for six 28-day "maintenance" cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additional time points throughout the trial. All patients also undergo collection of blood samples during screening and on study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Given PO
Andere Namen:
Undergo surgery
Andere Namen:
Undergo bone scintography
Andere Namen:
Undergo X-ray
Andere Namen:
|
|
Aktiver Komparator: Efficacy Phase Arm C (MAP)
High risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive "consolidation" with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additional time points throughout the trial. All patients also undergo collection of blood samples during screening and on study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo surgery
Andere Namen:
Undergo bone scintography
Andere Namen:
Undergo X-ray
Andere Namen:
|
|
Experimental: Efficacy Phase Arm D (cabozantinib, MAP)
High risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles, followed by appropriate local control. Patients then receive one 35-day "consolidation" cycle with methotrexate IV, doxorubicin IV, and cisplatin IV, then a second 35-day "consolidation" cycle with cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV, followed by two additional 35-day "consolidation" cycles with cabozantinib PO, methotrexate IV, and doxorubicin IV. Patients then receive cabozantinib PO for six 28-day "maintenance" cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additional time points throughout the trial. All patients also undergo collection of blood samples during screening and on study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Given PO
Andere Namen:
Undergo bone scintography
Andere Namen:
Undergo X-ray
Andere Namen:
|
|
Experimental: Feasibility phase (cabozantinib, MAP)
(CLOSED TO ACCRUAL 05/09/2025): Patients receive cabozantinib orally (PO), methotrexate intravenously (IV), doxorubicin IV, and cisplatin IV for two 35-day "induction" cycles. Patients are then considered for appropriate local control. Then they receive "consolidation" with methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, followed by cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, and cabozantinib PO, methotrexate IV, and doxorubicin IV for two 35-day cycles. Patients then receive cabozantinib PO for six 28-day "maintenance" cycles. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Given PO
Andere Namen:
Undergo surgery
Andere Namen:
Undergo bone scintography
Andere Namen:
Undergo X-ray
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Occurrence of dose-limiting toxicity (Feasibility)
Zeitfenster: Baseline up to 6 weeks
|
Only patients with high risk osteosarcoma who have a primary tumor considered resectable at the time of enrollment will be enrolled to this part of the trial. If a feasible dose cannot be established, the study committee will consult with Children's Oncology Group leadership and National Cancer Institute Cancer Therapy Evaluation Program regarding possible modifications of the regimen and subsequent protocol amendment. |
Baseline up to 6 weeks
|
|
Event-free survival (EFS) (Phase II)
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
The randomization and analysis will be stratified according to risk group. An assessment of the reduction in risk for EFS-event at the designated landmark time will be used to determine whether the trial continues to part 3. If the study proceeds to part 3, patients enrolled to part 2 of the trial will contribute to the primary analyses for part 3 of the study. If the interim criterion for continuation is not obtained, accrual will be closed with the conclusion that cabozantinib does not reduce sufficiently the risk for EFS-event for patients with newly-diagnosed osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS (Phase III)
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will consist of two randomized phase 3 sub-studies ('Phase 3'). One will be conducted in standard risk patients and one will be conducted in high risk patients. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
Overall survival
Zeitfenster: From randomization until death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
The one-sided logrank test will be the primary statistical methodology for assessing the null statistical hypothesis. The assessment of the reduction in risk of EFS-event will be conducted in standard risk patients and high risk patients separately. |
From randomization until death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will validate whether elevated circulating tumor deoxyribonucleic acid (ctDNA) levels greater than or equal to 5% at the time of diagnosis are associated with increased risk of EFS-event in patients with localized, resectable osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will validate whether elevated ctDNA levels greater than or equal to 5% at the time of diagnosis are associated with increased risk of EFS-event in patients with metastatic, pelvic and unresectable osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will validate whether elevated ctDNA levels greater than or equal to 3% after initiation of therapy and prior to definitive surgery are associated with increased risk of EFS-event in patients with localized, resectable osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will validate whether elevated ctDNA levels greater than or equal to 3% after initiation of therapy and prior to definitive surgery are associated with increased risk of EFS-event in patients with metastatic, pelvic and unresectable osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
Change in symptom burden and tolerability
Zeitfenster: Up to 5 years after completion of study treatment
|
Will determine whether methotrexate, doxorubicin, and cisplatin (MAP) chemotherapy plus cabozantinib results in increased symptom burden and decreased tolerability to patients as measured by patient reported therapy-specific acute toxicities (Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events [PRO-CTCAE]). |
Up to 5 years after completion of study treatment
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will determine whether ctDNA at diagnosis and early on-treatment, as a continuous measurement of ctDNA burden, is associated with an increased risk of EFS-event in patients with newly diagnosed osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will evaluate whether the magnitude of change in ctDNA levels from diagnosis to planned surgical procedure is associated with risk of EFS-event in patients with newly diagnosed osteosarcoma. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will determine whether ctDNA levels greater than or equal to 3% after planned surgical procedures are associated with increased risk of EFS-event. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
Will describe the presence of specific copy-number alterations, including MYC amplifications, detected in ctDNA and matched diagnostic tumor samples in patients with newly diagnosed osteosarcoma and determine whether frequently occurring copy-number alterations are associated with increased risk of EFS-event. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
|
|
ctDNA burden
Zeitfenster: Up to 5 years after completion of study treatment
|
Will determine whether ctDNA burden is predictive of response to the experimental therapy in patients with newly diagnosed osteosarcoma. |
Up to 5 years after completion of study treatment
|
|
Impact of combination therapy on symptom bother
Zeitfenster: Up to 5 years after completion of study treatment
|
Will prospectively compare the impact of combination therapy on symptom bother as measured by the Functional Assessment of Cancer Therapy-General Questionnaire item GP5 in patients with osteosarcoma receiving MAP chemotherapy with or without cabozantinib, and to assess the relationship between symptom bother and number of patient-reported acute toxicities (as measured by the PRO-CTCAE). |
Up to 5 years after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 1 year after completion of study treatment
|
Estimates of 1-year EFS for standard risk (SR) and high risk (HR) patients on each Arm MAP and Arm cabozantinib (CABO)-MAP and the corresponding 95% confidence intervals (CIs) by sex. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 1 year after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 1 year after completion of study treatment
|
Estimates of 1-year EFS for SR and HR patients on each Arm MAP and Arm CABO-MAP and the corresponding 95% CIs by race. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 1 year after completion of study treatment
|
|
EFS
Zeitfenster: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 1 year after completion of study treatment
|
Estimates of 1-year EFS for SR and HR patients on each Arm MAP and Arm CABO-MAP and the corresponding 95% CIs by ethnicity. |
From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 1 year after completion of study treatment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Michael W Bishop, Children's Oncology Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Sarkom
- Neubildungen, Binde- und Weichgewebe
- Neubildungen, Knochengewebe
- Neubildungen, Bindegewebe
- Osteosarkom
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenhydrate
- Physikalische Phänomene
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glykoside
- Ausrüstung und Vorräte
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Elemente
- Metalle
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Pterins
- Pteridine
- Metalle, schwer
- Aminopterin
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Platinverbindungen
- Elektromagnetische Phänomene
- Magnetische Phänomene
- Daunorubicin
- Übergangselemente
- Elektromagnetische Strahlung
- Strahlung
- Strahlung, ionisieren
- Methotrexat
- Doxorubicin
- Cisplatin
- 1,2-Diaminocyclohexanplatin-II-Citrat
- Magnetresonanzspektroskopie
- Chirurgische Eingriffe, operativ
- Platin
- Röntgenaufnahmen
- Cabozantinib
- Merphos
- Phantome, Bildgebung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2022-08567
- U10CA180886 (US NIH Stipendium/Vertrag)
- AOST2032 (Andere Kennung: CTEP)
- NCI-2022-08567 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- AOST2032 (Andere Kennung: Children's Oncology Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .